WO2004015096A8 - Extraits de sangsues pour stents - Google Patents

Extraits de sangsues pour stents

Info

Publication number
WO2004015096A8
WO2004015096A8 PCT/FR2003/002473 FR0302473W WO2004015096A8 WO 2004015096 A8 WO2004015096 A8 WO 2004015096A8 FR 0302473 W FR0302473 W FR 0302473W WO 2004015096 A8 WO2004015096 A8 WO 2004015096A8
Authority
WO
WIPO (PCT)
Prior art keywords
complex
activity
destabilase
stents
destabilase complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002473
Other languages
English (en)
Other versions
WO2004015096A3 (fr
WO2004015096A2 (fr
Inventor
Jacques Latrille
Guennady I Nikonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RICARIMPEX
Original Assignee
RICARIMPEX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RICARIMPEX filed Critical RICARIMPEX
Priority to JP2004526981A priority Critical patent/JP2005534331A/ja
Priority to AU2003282192A priority patent/AU2003282192A1/en
Priority to EP03756529A priority patent/EP1527169A2/fr
Priority to US10/523,937 priority patent/US20060110425A1/en
Publication of WO2004015096A2 publication Critical patent/WO2004015096A2/fr
Publication of WO2004015096A3 publication Critical patent/WO2004015096A3/fr
Anticipated expiration legal-status Critical
Publication of WO2004015096A8 publication Critical patent/WO2004015096A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626—Liposomes, micelles, vesicles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne un complexe de destabilase stable, sous forme de monomère, capable de s'agréger en complexe destabilase polymère formant un liposome, susceptible d'être obtenu à partir de sangsues médicinales par un procédé comprenant- une chromatographie d'affinité avec lesdits anticorps de la 6-keto­prostaglandine immobilisés sur une colonne appropriée ; - l'élution à force ionique élevée du complexe destabilase, ledit complexe présentant une activité antithrombine d'au moins 700 ATU/mg, une durée de recalcification du plasma d'au moins 800 APC/mg, une activité fibrinolytique d'au moins 40mm2/mg, et une activité immunomodulatrice.
PCT/FR2003/002473 2002-08-07 2003-08-06 Extraits de sangsues pour stents Ceased WO2004015096A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004526981A JP2005534331A (ja) 2002-08-07 2003-08-06 ステント用のヒル抽出物
AU2003282192A AU2003282192A1 (en) 2002-08-07 2003-08-06 Leech extracts for stents
EP03756529A EP1527169A2 (fr) 2002-08-07 2003-08-06 Extraits de sangsues pour stents
US10/523,937 US20060110425A1 (en) 2002-08-07 2003-08-06 Leech extracts for stents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/10042 2002-08-07
FR0210042A FR2843304B1 (fr) 2002-08-07 2002-08-07 Extraits de sangsues pour stents

Publications (3)

Publication Number Publication Date
WO2004015096A2 WO2004015096A2 (fr) 2004-02-19
WO2004015096A3 WO2004015096A3 (fr) 2004-04-08
WO2004015096A8 true WO2004015096A8 (fr) 2005-05-06

Family

ID=30470988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002473 Ceased WO2004015096A2 (fr) 2002-08-07 2003-08-06 Extraits de sangsues pour stents

Country Status (6)

Country Link
US (1) US20060110425A1 (fr)
EP (1) EP1527169A2 (fr)
JP (1) JP2005534331A (fr)
AU (1) AU2003282192A1 (fr)
FR (1) FR2843304B1 (fr)
WO (1) WO2004015096A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884829B1 (fr) * 2005-04-22 2008-01-11 Ricarimpex Procede d'obtention d'un extrait bacterien d'aeromonas hydrophila provenant de sangsues, et compositions pharmaceutiques les contenant
US8709473B1 (en) * 2009-01-28 2014-04-29 Abbott Cardiovascular Systems Inc. Method of targeting hydrophobic drugs to vascular lesions
CA2906633C (fr) * 2013-03-15 2021-11-30 Warner Chilcott Company, Llc Forme posologique de capsule de gelatine molle pharmaceutique comportant de la gomme de guar modifie
RU2560839C1 (ru) * 2014-03-20 2015-08-20 Общество с ограниченной ответственностью "Малое инновационное предприятие Центр экологических и оздоровительных технологий" Состав косметического средства геропротекторного действия

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243196B (it) * 1990-08-03 1994-05-24 Arval Spa Fogli di collagene nativo liofilizzato contenenti formulati cosmetici per il trattamento della couperose
RU2112528C1 (ru) * 1994-12-23 1998-06-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- ε(γ GLY)-LYS-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
RU2129429C1 (ru) * 1995-09-05 1999-04-27 Московское акционерное общество "Биокон" Способ выделения комплекса дестабилаза - простагландин из медицинской пиявки
BR9712332A (pt) * 1996-10-15 2004-06-29 Procter & Gamble Composições detergentes contendo isopeptidade
WO2001047572A2 (fr) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Dispositif et constituant actif destines a inhiber la formation de thrombus-matrice cellulaire inflammatoire

Also Published As

Publication number Publication date
FR2843304B1 (fr) 2005-12-16
AU2003282192A1 (en) 2004-02-25
WO2004015096A3 (fr) 2004-04-08
FR2843304A1 (fr) 2004-02-13
US20060110425A1 (en) 2006-05-25
JP2005534331A (ja) 2005-11-17
EP1527169A2 (fr) 2005-05-04
WO2004015096A2 (fr) 2004-02-19

Similar Documents

Publication Publication Date Title
WO2004030011A3 (fr) Procede et appareil destines a une plaque d'une electrode superieure amelioree dans un systeme de traitement au plasma
AU2001224729A1 (en) Segmented electrode assembly and method for plasma processing
WO2002016927A3 (fr) Interface d'introduction d'échantillon pour traitement analytique
EP1137089B8 (fr) Séparateur de gaz pour pile à combustible, méthode de fabrication et pile à combustible
AU1747697A (en) Multi-pieced, portable projection dome and method of assembling the same
WO1998016507A3 (fr) Nouveaux derives de pyrazol heterocyclylmethyle-substitues
AU2001259557A1 (en) Method of adjusting the thickness of an electrode in a plasma processing system
AU2003279229A1 (en) Fuel cell assembly and method of making the same
AU5693199A (en) Plasma reactor with electrode arrangement for providing a grounding path for theplasma, and method of manufacturing the same
AU2045499A (en) Cuff electrode and method for manufacturing the same
EP1182383A3 (fr) Segment de compression
WO1999029878A3 (fr) Procede de production de proteines anti-angiogeniques, dont l'endostatine, l'angiostatine ou la restine, au moyen d'un systeme d'expression de la levure pichia
WO2003049746A3 (fr) Combinaison d'inhibiteurs de protease dependant du cytochrome p450
AU2002304247A1 (en) Method for producing composite material for electrode comprising quinoxaline based polymer, such material, electrode and battery using the same
AU5066099A (en) Method for processing soybean by using enzyme, processed soybean thus obtained and foods containing the thus processed soybean
AU3425700A (en) Non-ribosomal peptide synthetases, method for producing same and the use thereof
AU6438194A (en) Method for the oxidation of vicinal diols, including carbohydrates
WO2004015096A3 (fr) Extraits de sangsues pour stents
AU2002246091A1 (en) Electrolyte membrane, membrane electrode units comprising the same, method for the production thereof and specific uses therefor
WO2001034951A3 (fr) Dispositif de terminal de detection de gaz et procede de production correspondant
WO2004008286A3 (fr) Dispositifs et procedes pour traiter un patient
AU2764497A (en) Alpha-glucuronidases of aspergillus, production thereof and their uses
WO2000001841A3 (fr) Analogues d'acide hyaluronique et procedes correspondants
WO1999002659A3 (fr) Procede de modification des domaines de la cyclosporine synthetase pour l'obtention d'une cyclosporine synthetase modifiee
AU2001252591A1 (en) Novel promoters and gene expression method by using the promoters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004526981

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003756529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003756529

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 08/2004 UNDER (72, 75) THE ADDRESS OF "NIKONOV, GUENNADY, I." SHOULD READ "KAMENSKY DISTRICT, PES OKTOBRIASKAYA 40, MOSCOW (RU)"

ENP Entry into the national phase

Ref document number: 2006110425

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10523937

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10523937

Country of ref document: US